**Core Concept**
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, a class of oral hypoglycemic agents used to treat type 2 diabetes mellitus. DPP-4 inhibitors work by increasing the levels of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin release and decrease glucagon levels in a glucose-dependent manner.

**Why the Correct Answer is Right**
Sitagliptin inhibits DPP-4, preventing the breakdown of incretin hormones. This leads to increased levels of GLP-1 and GIP, which in turn stimulate insulin release from the pancreatic beta cells and decrease glucagon secretion from the pancreatic alpha cells. The increased insulin release and decreased glucagon levels result in improved glycemic control. Sitagliptin does not have a significant effect on pancreatic beta-cell mass or function, making it a suitable option for patients with a history of cardiovascular disease.

**Why Each Wrong Option is Incorrect**
**Option A:** (No information provided for this option)
However, if we were to provide a potential distractor, it might be something like "Sitagliptin is a sulfonylurea." This would be incorrect because sitagliptin is not a sulfonylurea; it is a DPP-4 inhibitor.

**Option B:** (No information provided for this option)
Another potential distractor might be "Sitagliptin is contraindicated in patients with kidney disease." While it is true that sitagliptin is primarily excreted by the kidneys, it is not contraindicated in patients with kidney disease. In fact, the dosage of sitagliptin may need to be adjusted in patients with moderate to severe renal impairment.

**Option C:** (No information provided for this option)
A potential distractor might be "Sitagliptin is a meglitinide." This would be incorrect because sitagliptin is not a meglitinide; it is a DPP-4 inhibitor.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that DPP-4 inhibitors like sitagliptin do not cause hypoglycemia when used as monotherapy, making them a suitable option for patients who are at risk of hypoglycemia.

**Correct Answer:**